| Bioactivity | BODIPY FL prazosin is a fluorescent α1-adrenergic antagonist with Ki values of 14.5, 43.3 nM for α1a-AR and α1b-AR, respectively. BODIPY FL prazosin also is a fluorescent ligand with the excitation and emission wavelengths are 485 and 535 nm, respectively. BODIPY FL prazosin can be used for study the differences in the subcellular localization of α1-adrenoceptor subtypes[1][2][3]. |
| Invitro | BODIPY FL prazosin (10 nM; 30 min at room temperature in 100 μl; COS-7 cells) shows Affinity of various α1-AR ligands with Ki values of 14.5, 43.3 nM for α1a-AR and α1b-AR, respectively[1].BODIPY FL prazosin (100 nM, 30 min) can be used as molecular probe for the Visualization of the non-adrenoceptor binding site of α1-adrenergic drugs in erythroleukemia cells[3]. |
| Name | BODIPY FL prazosin |
| CAS | 175799-93-6 |
| Formula | C28H32BF2N7O3 |
| Molar Mass | 563.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sugawara T, et al. Differences in the subcellular localization of alpha1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. Life Sci. 2002 Mar 22;70(18):2113-24. [2]. Cerveny L, et al. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. Epilepsia. 2006 Mar;47(3):461-8. [3]. Fuchs R, et al. α1-adrenergic drugs exhibit affinity to a thapsigargin-sensitive binding site and interfere with the intracellular Ca2+ homeostasis in human erythroleukemia cells. Exp Cell Res. 2011 Dec 10;317(20):2969-80. |